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Osteoporosis is characterized by skeletal degeneration with low bone mass and destruction of microarchitecture of bone tissue
which is attributed to various factors including inﬂammation. Women are more likely to develop osteoporosis than men
due to reduction in estrogen during menopause which leads to decline in bone-formation and increase in bone-resorption
activity. Estrogen is able to suppress production of proinﬂammatory cytokines such as IL-1, IL-6, IL-7, and TNF-α. This is
why these cytokines are elevated in postmenopausal women. Studies have shown that estrogen reduction is able to stimulate
focal inﬂammation in bone. Labisia pumila (LP) which is known to exert phytoestrogenic eﬀect can be used as an alternative to
ERT which can produce positive eﬀects on bone without causing side eﬀects. LP contains antioxidant as well as exerting anti-
inﬂammatory eﬀect which can act as free radical scavenger, thus inhibiting TNF-α production and COX-2 expression which leads
to decline in RANKL expression, resulting in reduction in osteoclast activity which consequently reduces bone loss. Hence, it is the
phytoestrogenic, anti-inﬂammatory, and antioxidative properties that make LP an eﬀective agent against osteoporosis.
1.Introduction
Plant has been one of the sources of medicine to treat
various illnesses and diseases since ancient time. In the early
19th century, when chemical analysis ﬁrst became available,
scientists began to extract and modify the active ingredients
fromplantswhichlaterledtowidedevelopmentofnaturalor
traditional medicine that was mostly passed on orally from
one generation to another. More than 35,000 plant species
have been reported to be used in various human cultures
around the world for their medical purposes [1]. Traditional
medicine has been deﬁned by the World Health Organi-
zation (WHO) as “health practices, approaches, knowledge
and beliefs incorporating plant, animal and mineral-based
medicines, spiritual therapies, manual techniques and exer-
cises, applied singularly or in combination, to treat, diagnose
and prevent illnesses or maintain well-being” [2].
Currently in Malaysia, over 2,000 species of lower plants
with medicinal and therapeutic properties have been identi-
ﬁ e d ,a n dm o s to ft h e mh a v eb e e nu s e df o rm a n yg e n e r a t i o n s
in various health care systems. About 17.1% of Malaysians
used herbs to treat their health problems while 29.6% of
them consumed herbs for their health maintenance [3]. The
earliest report on medicinal plant research in Malaysia was
carried out by Arthur in 1954 [4]. Subsequently, more plants
were screened chemically for alkaloids, saponins, triterpenes,
and steroids in the 90s [5, 6].
Amongst the famous herbs that are widely used in
Malaysia by the locals are Labisia pumila (Kacip Fatimah),
Eurycoma longifolia Jack (Tongkat Ali), Orthosiphon stamin-
eus (Misai Kucing), Quercus infectoria (Manjakani), and
Piper sarmentosum (daun kaduk). These plants are similar
in terms of exhibiting phytochemical properties that are
protective against various diseases. These herbs are known
to exert antibacterial, antioxidant, and anti-inﬂammatory
properties that make them beneﬁcial against many types of
diseases such as fever, asthma, joint pains, gastrointestinal
diseases, bone disorders, and inﬂammatory disorders. [7–9].
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and health beneﬁts of one of the famous Malaysian herbs,
Kacip Fatimah.
Kacip Fatimah or its scientiﬁc name Labisia pumila (LP)
is a member of small genus of slightly woody plants of
the family Myrsinaceae. There are four known varieties of
Labisia pumila found in Malaysia but only three of them
are widely used by the locals, which are recognized as
Labisia pumila var. pumila, Labisia pumila var. alata, and
Labisia pumila var. lanceolata [10, 11]. LP is found mainly
in the lowland and hillforests of peninsular Malaysia at
an altitude between 300 and 700 metres. It is also known
by the locals as Selusuh Fatimah, Rumput Siti Fatimah,
Akar Fatimah, Pokok Pinggang, and Belangkas Hutan [12,
13]. Of all the subtypes, Labisia pumila var. alata is the
most widely used by the locals [10]. Its water extract is
traditionally consumed especially by the Malay women to
treat menstrual irregularities and painful menstruation, help
contracting birth channel after delivery, and to promote
sexual health function [14, 15]. It has also been used to treat
dysentery, gonorrhoea, rheumatism, and sickness in bones
[16, 17].
It is the phytoestrogen, anti-inﬂammatory, and antiox-
idative properties that make LP eﬀective against various
illnesses. LP was reported to exert estrogenic properties [18–
20]. Theoretically, phytoestrogens can act as anti-estrogenic
agents by blocking the estrogen receptors and exerting
weaker estrogenic eﬀect compared with the hormone [21].
The water extract of LP has been found to inhibit estradiol
binding to antibodies raised against estradiol, suggesting
the presence of estrogen-like compounds in the extract
[22]. It also contains triterpene and saponins, including the
compound ardisiacrispin A which were thought to be the
reason behind the phytoestrogenic activity of LP [23].
LPhasbeenwidelyusedbythelocalsinMalaysianotonly
to ease menstrual pain, induce labor, and promote healthy
sexualfunctionbutitisalsousedasanalternativetoestrogen
replacement therapy in postmenopausal women [24, 25].
Postmenopausal women are prone to osteoporosis due to
the reduction in estrogen level. Estrogen acts on estrogen
receptor-α (ERα)a n dr e c e p t o r - β (ERβ) which has high
aﬃnity towards osteoblasts and osteoclasts [26]. Activation
of estrogen-receptor complex is vital in maintaining bone
remodelling processes [27]. Estrogen can induce osteoclasts
apoptosis and inhibit osteoblasts apoptosis, which indirectly
will reduce bone resorption and increase bone-formation
activity [28]. Hence, reduction in estrogen is highly associ-
ated with bone loss. Dietary phytoestrogens such as LP can
be an alternative to synthetic estrogen for hormone therapy
to reduce side eﬀects of prolonged hormone therapy such as
risk of breast cancer, endometrial cancer, and cardiovascular
diseases [29, 30]. This paper will focus on the role of Labisia
pumila in oﬀering protection against postmenopausal osteo-
porosis via its anti-inﬂammatory properties.
2. Anti-Inﬂammatory Role of Labisia pumila
Osteoporosis is characterized by skeletal degeneration with
low bone mass and destruction of microarchitecture of
bone tissue. According to the National Institute of Health,
osteoporosis is a skeletal disease which involves decline
in mass and density which later leads to fracture [31].
Women, especially postmenopausal women, are more likely
to develop osteoporosis than men due to tremendous decline
in estrogen during menopause which will lead to decline
in bone formation and increase in bone-resorption activity
[32]. Osteoporosis is attributed to various factors, and
there are evidences that inﬂammation also exerts signiﬁcant
inﬂuence on bone turnover, inducing osteoporosis [33, 34].
According to studies by Lorenzo and Manolagas and Jilka,
certain pro-inﬂammatory cytokines play potential critical
roles both in the normal bone remodeling process and
in the pathogenesis of osteoporosis [34, 35]. For example,
interleukin- (IL-) 6 promotes osteoclasts diﬀerentiation and
activation [36]. IL-1 is another potent stimulator of bone
resorption [37] that has been linked to the accelerated bone
loss seen in postmenopausal osteoporosis [38].
Various epidemiologic studies reported an increase in
the risk of developing osteoporosis in various inﬂammatory
conditions such as rheumatoid arthritis, haematological
diseases, and inﬂammatory bowel disease [39, 40]. Proin-
ﬂammatory cytokines such as tumor necrosis factor (TNF)-
α, IL-6, IL-1, IL-11, IL-15, and IL-17 are elevated in these
conditions [41]. IL-6 and IL-1 may inﬂuence osteoclastogen-
esis by stimulating self-renewal and inhibiting the apoptosis
of osteoclasts progenitors [42, 43]. They promote osteoclasts
diﬀerentiation which is an important stimulator of bone
resorption that has been linked to accelerated bone loss
seen in postmenopausal women [36]. Receptor activator of
NF-κβ ligand (RANKL) is a membrane-bound molecule of
TNF ligand family which plays a crucial role in osteoclasts
formation [44]. TNF is a cytokine that is involved in inﬂam-
mation and is an important cofactor in bone resorption
because this cytokine supports osteoclasts activation medi-
ated by RANKL and c-Fms/macrophage colony-stimulating
factor.
Estrogen is able to suppress the production of these
proinﬂammatory cytokines [45, 46]. This is why estrogen
withdrawal following menopause will lead to increase in
these cytokines as proven in many studies. Studies on bone
resorption demonstrated that the fall of estrogen level in
postmenopausal women was able to stimulate local inﬂam-
mation in the bone. Ovariectomy in rats was accompanied
by increased production of IL-1 and TNF-α which later
resulted in decrease in bone density. Hence, it is suggested
that estrogen withdrawal can be associated with an increase
in production of proinﬂammatory cytokines, which in turn
increases osteoclasts activity resulting in profound bone loss
[47]. Estrogen will stimulate production of osteoprotegerin
(OPG), which is a potent antiosteoclastogenic factor. OPG
acts as a decoy, blocking the binding of the RANK expressed
in osteoblasts progenitors, to RANKL which is expressed
in committed preosteoblastic cells [48]. This estrogen deﬁ-
ciency leads to upregulation of cytokines [49]a n dd o w n -
regulation of OPG which will result in increase in inﬂam-
matory responses and increase in bone-resorption activity.
In a study by Collin-Osdoby et al., [50] increases in RANKL
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following an inﬂammatory stimulus. Therefore, suppression
of these potent inﬂammatory mediators has been proposed
toexplainthedeleteriouseﬀectsofestrogendeﬁciencyonthe
human skeletal system at menopause.
3. Phytoestrogenic Role of Labisia pumila
LP which has been opposed to exert phytoestrogen property
can be used as an alternative to estrogen replacement therapy
(ERT)inpostmenopausalinﬂammation-inducedosteoporo-
sis. In contrast to ERT which can cause many harmful side
eﬀects, LP which originated from natural resources will not
cause any side eﬀect, if taken within its safe therapeutic
dose. Toxicity testing of LP which was done by the Herbal
Medicine Research Centre of Institute of Medical Research
has shown that LD50 is safe at more than 5.0g/kg [51]. LP
extractwasfoundtoexhibitno-adverse-eﬀectlevel(NOAEL)
at the dose of 50mg/kg in subacute toxicity study [52],
1000mg/kg in subchronic toxicity study [53], and 800mg/kg
in reproductive toxicity study [51]. Therefore,LP is safe to be
g i v e na th i g hd o s ea sl o n ga si td o e sn o to u t w e i g ht h et o x i c
dose.
Studies have shown that production of proinﬂammatory
cytokinesinresponsetoestrogenwithdrawalatmenopauseis
responsibletothestimulationofosteoclasticboneresorption
[54–56]. A study done by Choi et al. [57] indicated that the
LP extract may have good potential to be developed as novel
anti-inﬂammatory drug due to an experimental ﬁnding of
treatment with LP extract which has markedly inhibited
the TNF-α production and the expression of cyclooxygenase
(COX)-2. COX-2 is an enzyme that is responsible for the
production of mediators involved in inﬂammation. In vitro
experiments have revealed increased COX-2 expression after
stimulation with proinﬂammatory cytokines, such as IL-1
and TNF-α [58].
Pharmacological inhibition of COX can provide a relief
from the symptoms of inﬂammation and pain. Studies have
shown that COX-2 plays an important role in pathophys-
iology of osteoporosis by stimulating the production of
prostaglandin (PGE2). Excessive PGE2 production might
lead to increase in bone resorption, while deﬁcient of its
productionmightimpairthebone-formationresponse,both
to mechanical loading and remodelling [59]. Consequently,
inhibition of the COX-2 enzyme in postmenopausal women
may prevent menopausal bone loss [60]. Inhibition of
the main proinﬂammatory cytokines has proven that LP
extract could be a good material for the regulation of anti-
inﬂammation process. TNF has been shown to stimulate
osteoclast diﬀerentiation, increase its activation, inhibit its
apoptosis, and inhibit osteoblast diﬀerentiation [61–63].
It also reduces bone formation in cultured osteoblast in
vitro [64]. Similar to IL-1, TNF-stimulated induction of
osteoclast-like-cell formation in bone marrow culture is
mediated by increases in RANKL expression. However, in
addition to increasing RANKL expression, TNF also inhibits
OPGinanosteoblasticmodel[65].Hence,inhibitionofTNF
will indirectly help in reducing bone loss.
4.AntioxidativeRole of Labisia pumila
Based on previous studies, LP has been shown to exhibit
antioxidative properties due to the presence of ﬂavanoids,
ascorbic acid, beta-carotene, anthocyanin, and phenolic
compounds [66, 67]. According to Norhaiza et al. [68], there
were positive correlations between the antioxidant capacities
and the antioxidant compounds of LP extract with β-
carotene having the best correlation, followed by ﬂavonoid,
ascorbicacid,anthocyanin,andphenoliccontent.β-carotene
is one of the basic constituent of antioxidative eﬀect. The
chemical abilities of β-carotene to quench singlet oxygen and
to inhibit peroxyl free radical actions are well established
[69]. Flavonoid has been shown to be highly eﬀective
scavenger of free radicals that are involved in diseases such
as osteoporosis and rheumatism which is associated with
aging due to oxidative stress [70]. Anthocyanin and phenolic
on the other hand, not only play a role as antioxidative
agents, but also as anti-inﬂammatory agents [71–73]. These
antioxidative and anti-inﬂammatory properties of LP extract
explained the eﬀectiveness of this medicinal plant against
various diseases such as osteoporosis, rheumatism, and
women sexual function.
Osteoporosis in postmenopausal women can also be
explained in terms of oxidative stress mechanism. Ovariec-
tomy has been proposed by many studies as a model of post-
menopausal osteoporosis. Following ovariectomy, decline in
estrogen level will result in signiﬁcant bone loss due to
bone resorption outweighing bone-formation activity [74].
Estrogen can be considered as an antioxidant as it was
found to exhibit antioxidant protection of lipoproteins in
the aqueous system [75] and was also shown to increase
the expression of glutathione peroxidase in osteoclasts [76].
That is why decline in estrogen will lead to increase in
osteoclasts activity resulting in bone loss. Free radicals
are continuously produced in the body, mostly by bio-
chemical redox reactions involving oxygen, which occur
as part of normal cell metabolism. Free radicals, mainly
reactive oxygen species (ROS), are eﬃciently scavenged, but
oxidative stress occurs when there is an imbalance between
increased ROS and inadequate antioxidant activity [77]
which consequently accelerates aging process and leads to
degenerative diseases such as osteoporosis, rheumatism, and
cardiovascular disease.
ROS alter mitochondrial and nuclear DNA integrity by
increasing the risk of mutations. When DNA repair mech-
anisms are overwhelmed, cells undergo apoptosis which
will lead to tissue damage [78]. This can be applicable in
postmenopausal osteoporosis mechanism. When body is
subjected to high oxidative stress following estrogen reduc-
tion, lipid accumulation will occur. Lipid peroxidation will
promote osteoblast apoptosis and simultaneously upregulat-
ing ROS production [79, 80]. ROS was shown to promote
osteoclast resorption activity either directly or mimicking
RANK signalling and stimulating osteoclast diﬀerentiation,
or indirectly, by stimulating osteoblast/osteoclast coupling
and subsequent osteoclast diﬀerentiation [81]. Oxidative
stresshasbeenaccededasamajorcontributortotheimmune
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characterized by establishment of an inﬂammatory response.
Thus, osteoporosis can be associated with inﬂammatory
mechanism.
Estrogen can prevent osteoblast cell death and RANKL
stimulation by suppressing ROS. Estrogen deﬁciency is a
key step in ROS-mediated stimulation of bone loss via
TNF-α signalling pathway. Stimulation of this proinﬂam-
matory cytokine will induce bone resorption by indirectly
aﬀecting production of essential osteoclast diﬀerentiation
factor, thereby enhancing proliferation of osteoclast lineage
[82]. Glutathione peroxide (GPx) and superoxide dismutase
(SOD) are the main antioxidative enzymes that play a pivotal
role in counteracting oxidative stress [83]. These enzymes
were found to be lowered in postmenopausal women with
osteoporosis. This failure of antioxidant defences will result
in deleterious eﬀe c to fh y d r o g e np e r o x i d eo nb o n eh e a l t h
[84].Studiesofantioxidantsupplementationsuchasvitamin
E on postmenopausal rat model have shown that lipid
peroxidation was successfully inhibited and antioxidative
enzymes were restored to acceptable level. In study by
Norazlina et al. (2007), IL-6 level was high in ovariectomised
rats showing high bone resorption rate, and this level
was signiﬁcantly reduced after three months of tocotrienol
(vitamin E) supplementation. In the same study, vitamin E-
deﬁcient rats given palm vitamin E showed an improvement
in bone calcium content and reduced bone resorption
marker[85].Hence,itisshownthatantioxidantiseﬀectivein
reducing bone-resorption activity as well as improving bone
calcium content.
Main antioxidative compound in LP such as ﬂavonoid
and β-carotene has been shown in previous studies to inhibit
production of nitric oxide and expression of inducible nitric
oxidesynthase(iNOS)[86]mostlik elybysuppressionofNF-
κB[ 87]. NF-kB is an oxidative stress-responsive transcrip-
tion factor which is activated by free radicals, inﬂammatory
stimuli, and other cytokines. Thus, free radicals may increase
bone resorption through activation of NF-kB. It has previ-
ously been shown in vitro and in rodents that free radicals
are involved in osteoclastogenesis and in bone resorption
[88]. Oxidative stress may increase bone resorption through
activation of NF-κB which plays an important role in
osteoclastogenesis [89, 90]. Hence, supplementation of LP
which contains antioxidative properties can reduce oxidative
stress level which indirectly prevents bone loss.
According to a recent study by Nazrun et al. (2011),
osteocalcin, a bone formation marker, was found to be
lowered in ovariectomised rats. After being treated with
LP results showed an increase in osteocalcin to the level
seen in sham-operated group indicating normalisation of
bone formation. Bone resorption marker, CTX on the other
hand, was found to be reduced after the rats were treated
with LP [91]. CTX is sensitive and speciﬁc in detection of
osteoporosis [92]. This result showed that LP was as eﬀective
as estrogen in preventing changes in bone markers induced
by ovariectomy.
Based on its positive eﬀects on the bone markers of
ovariectomisedratswhicharecomparabletoestrogenandits
safetyproﬁle,LPhasthepotentialtobeusedasanalternative
treatment for postmenopausal osteoporosis. All in all, it is
the anti-inﬂammatory, phytoestrogenic, and antioxidative
properties of LP that make it an eﬀective natural medicine
in treatment and prevention of osteoporosis.
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